Research progress on the regulation of microRNAs by traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2025.101072 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Yanran Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs, Medicine, Chinese Traditional. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
This review systematically summarizes the research progress on the regulation of microRNAs (miRNAs) by traditional Chinese medicine (TCM) in the prevention and treatment of hepatocellular carcinoma (HCC). As one of the most prevalent and lethal malignancies worldwide, the efficacy of current therapeutic strategies for HCC remains limited due to tumor heterogeneity and drug resistance, necessitating the exploration of novel treatment approaches. TCM, with its multi-target regulatory advantages, has demonstrated unique potential in influencing HCC progression by modulating miRNA expression, thereby affecting tumor cell proliferation, apoptosis, and invasion. This review provides an in-depth discussion of the biological pathways involved in TCM-mediated miRNA regulation, including transmembrane transport, targeted modulation, and bio-carrier-mediated delivery mechanisms. The dual role of miRNAs in HCC as either tumor suppressors or oncogenes is extensively analyzed. Moreover, we highlight the key mechanisms by which TCM modulates miRNA expression, such as epigenetic regulation, signal transduction pathway intervention, and anti-inflammatory and immunoregulatory effects, ultimately influencing HCC progression. Additionally, the clinical significance of serum miRNAs in HCC diagnosis, prognosis assessment, and correlation with pathological characteristics is discussed. Finally, we explore the challenges and future directions in HBV-associated HCC treatment via miRNA modulation, providing new insights into HCC prevention and therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China.
- Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.
- Hubei University of Chinese Medicine, Wuhan, Hubei 430065, China.
- Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. Electronic address: D202181725@hust.edu.cn.
- Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China; Yancheng Hospital of Traditional Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Yancheng, J…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, Y., Deng, Y., Wang, Y., Li, J., & Pan, G. (2026). Research progress on the regulation of microRNAs by traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.101072
Vancouver
Wu Y, Deng Y, Wang Y, Li J, Pan G. Research progress on the regulation of microRNAs by traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2025.101072
BibTeX
@article{Wu2026,
author = {Wu, Yanran and Deng, Yu and Wang, Yuhan and Li, Jinxiao and Pan, Guangtao},
title = {Research progress on the regulation of microRNAs by traditional Chinese medicine in the prevention and treatment of hepatocellular carcinoma},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2025.101072}
}
EUVIMED